Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included representatives from Shenzhen Century Quantum and various other individuals [2] - The meeting took place on December 12, 2025, at the company's headquarters [2] Group 2: Purpose of the Meeting - The main objective was to understand the company's production and operational status [2]

Group 1: Investor Meeting Overview - The investor meeting was attended by 32 participants from various institutions, including Hongsike Asset, Guangzhou Shuncong Investment, and Shenzhen Qichuang Group [1] - The meeting took place on December 12, 2025, at the company's headquarters [1] - The reception was managed by the investor relations team, specifically Zhang Yu and Yang Kexin [1] Group 2: Meeting Purpose - The primary focus of the meeting was to understand the company's production and operational status [1]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical business group achieved a main business revenue of CNY 4.751 billion, a year-on-year increase of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded CNY 1.453 billion, with a significant year-on-year growth of over 20.9% [2] - Other traditional Chinese medicine products showed remarkable growth, with sales of Canling Jianpi Granules exceeding CNY 100 million and Pudilan Anti-inflammatory Tablets nearing CNY 100 million [2] Group 2: Online Sales and Marketing - The pharmaceutical business group expanded its online market, with O2O sales increasing by over 20% year-on-year [3] - During the 2025 "618" shopping festival, the company’s main products ranked significantly higher on the regular medicine list [3] - E-commerce platforms attracted 48.45 million visitors, resulting in 3.54 million consumers and generating a GMV of CNY 254 million [3] Group 3: Health Products Strategy - The health products group aims to become a leader in high-quality health lifestyle products, focusing on oral care and hair care [4] - Continuous enhancement of oral product advantages and rapid scaling of hair care business are key objectives for the second half of the year [4] Group 4: Nuclear Medicine Development - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [5] - The INR102 therapeutic nuclear medicine project has received clinical trial approval, with 12 patients enrolled in Phase I trials [5] Group 5: Traditional Chinese Medicine Resource Development - The Chinese medicine resource group focuses on Yunnan's local medicinal materials, achieving significant results through collaborative efforts [6] - The establishment of 14 seed source bases and the completion of 90% of the annual target for quality seed promotion [6] - The digital cloud medicine platform achieved a transaction volume exceeding CNY 1 billion, with 18,000 registered farmers [6] Group 6: Future Directions for Provincial Pharmaceutical Company - The provincial pharmaceutical company plans to enhance market share in existing hospitals and distribution channels while exploring new growth areas [8] - Strategies include optimizing supply chain management and improving accounts receivable and inventory structure [8]

Group 1: Marketing and Sales Performance - In the first half of 2025, the pharmaceutical business group achieved over 20% year-on-year growth in O2O sales, leveraging platforms like Douyin and Xiaohongshu for extensive content marketing [2][3] - Online sales reached a GMV of 254 million CNY, with 48.45 million visitors and 3.54 million consumers driven to e-commerce platforms [3] - The company’s strategic partnership with JD Health significantly improved the ranking of its main products during the 2025 618 shopping festival [3] Group 2: Traditional Chinese Medicine (TCM) Resource Development - The TCM resource business group generated 914 million CNY in external revenue in the first half of 2025, reflecting a year-on-year growth of approximately 6.3% [4] - The group implemented a "six unifications" operational model to enhance the TCM supply chain, focusing on unified planting, sourcing, standards, processing, sales, and management [4] Group 3: Research and Development Progress - The company is advancing 16 major TCM projects, with 37 ongoing initiatives, focusing on secondary development and innovative drug creation [6] - Clinical trials for key products like Qixuekang and Gongxuening are progressing, with significant milestones achieved in various phases of testing [6] Group 4: Dividend Distribution - For the 2024 fiscal year, the company announced a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.16 billion CNY, which represents 90.09% of the net profit attributable to shareholders [7] - In the first half of 2025, a cash dividend of 10.19 CNY per 10 shares was distributed, amounting to 1.82 billion CNY, which is 50.05% of the net profit for that period [8] Group 5: Digital Transformation Initiatives - The company is implementing a digital development plan (2022-2026) that integrates data and AI across key operational areas, enhancing efficiency and innovation [9][10] - A self-developed marketing operations platform has improved channel efficiency, reducing manual processing workload by 30% and eliminating 60,000 paper documents annually [9] - The digitalization of the TCM supply chain has significantly reduced transaction times from one day to mere minutes, enhancing overall operational efficiency [11]

Group 1: Commercial Space Business Development - The company is conducting feasibility studies for the production line of commercial rocket fuel tanks, focusing on compatibility and investment efficiency based on market trends and customer needs [2] - The maturity of reusable technology is expected to enhance launch frequency and operational efficiency, leading to increased demand for new rocket structures, thus creating new business growth opportunities [4] - The company is actively expanding its customer base in the commercial space sector and has made substantial progress, with new customer orders expected to enter mass cooperation in Q1 of the following year [4] Group 2: Manufacturing Capabilities and Market Position - The company completed the construction of a riveting production line in the first half of 2024, with an annual capacity of 10 units, and is prepared to expand capacity based on order demand [4] - The manufacturing of rocket structural components is currently constrained by supply, with a limited number of suppliers capable of large-scale delivery, indicating a strong market position for the company [5] - The company has established stable, small-batch product deliveries to leading private rocket companies, leveraging its experienced team and financial resources for equipment purchases and production line construction [5] Group 3: Aerospace and Automotive Business Performance - The aerospace business has shown improvement due to recovering customer demand and product optimization, with ongoing efforts to enhance production organization and delivery capabilities [6] - The automotive sector has experienced stable revenue growth, although profit margins have fluctuated due to material cost increases and depreciation from new projects [7] - The company anticipates enhanced profitability in the automotive sector by 2026, driven by optimized capacity structure and increased high-value product ratios [8] Group 4: Growth Drivers in Automotive Sector - Key growth drivers for the automotive business include expanding exports, new customer development, product category expansion, and increased industry concentration [8] - Strategic partnerships with international suppliers like Magna, Valeo, and Bosch provide a solid foundation for overseas market expansion [8]

Group 1: Company Overview and Industry Position - The company focuses on three strategic industries: rail transportation, aerospace, and nuclear industry, establishing a diversified industrial layout with three main business segments [3] - The subsidiary, XuanYu Intelligent, has become a significant supplier in the domestic special robot and intelligent equipment sector, particularly in high-radiation environments [3] Group 2: Future Development Plans - The company aims to strengthen key technology research and development in its three core areas, enhance marketing systems, and improve brand influence to increase market competitiveness [4] - Plans include the introduction and cultivation of professional talent in key areas such as technology R&D and supply chain management to enhance operational efficiency and risk resistance [4] Group 3: Market Challenges and Strategies - The company acknowledges the intensifying competition in the rail transportation industry and plans to leverage digital economy opportunities to drive innovation and traditional industry upgrades [6] - Strategies to counteract increased competition include expanding brand influence and market share through continuous innovation and value extension [6] Group 4: Investor Relations and Governance - Independent directors have actively worked to improve the company's information disclosure mechanisms, ensuring timely and accurate communication with minority investors [6] - The company is focused on cultivating leading talents and enhancing management professionalism to build a competitive workforce [6] Group 5: Strategic Adjustments in Response to National Policies - The company is aligning its strategies with national policies by focusing on quality improvement in its main business, enhancing R&D in key sectors, and optimizing capital structure for better resource allocation [8]

Group 1: Investment in Emerging Technologies - The company has invested in a series of quality enterprises in artificial intelligence and embodied intelligence, covering sectors such as silicon carbide devices, medical diagnostic models, spatial AI generation, embodied intelligent robots, and edge intelligent chips [2][4]. - In the commercial aerospace and low-altitude economy sectors, the company has incubated representative enterprises like Zhongke Xingrui Technology and Guangzhou Chengxing Communication Technology, focusing on satellite systems and electric vertical takeoff and landing (eVTOL) technology [2][3]. Group 2: Unique Advantages and Project Selection - The company's core advantage lies in its ability to gather, explore, and incubate quality technological innovation resources, significantly reducing entrepreneurial risks and enhancing success rates for early-stage projects [4][5]. - The company leverages its deep experience with Tsinghua University in project selection, considering multiple dimensions such as technology, team, finance, and industry to ensure scientific and forward-looking decision-making [5]. Group 3: Future Growth Drivers - Future profit growth will be driven by deepening the integration of industry, academia, and research, creating an innovative community focused on value co-creation, and exploring new paths for industry cultivation [5]. - The company aims to promote exits from quality projects already invested in, injecting sustainable momentum into its development [5].

Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established in 1993, focusing on the R&D, production, and sales of medical devices. It is recognized as a national industrialization base for multi-parameter monitors and a national champion enterprise in manufacturing [1] - The company’s monitoring equipment is utilized in thousands of medical institutions, with a diverse product range including integrated monitors, modular monitors, and portable monitors, as well as infusion pumps and ECG machines [1] Product Development and Innovation - Recent product launches include the D800 series dialysis machines, P series modular monitors, home peritoneal dialysis machines, S series infusion pumps, and visual laryngoscopes, featuring industry-leading technologies [2][3] - The P series modular monitor won the "Red Dot Award" for its advanced features such as anti-electrosurgical interference technology and intelligent voice assistance [2] Market Trends and Policies - The "old-for-new" policy for medical devices positively impacts the company's monitoring equipment business, increasing demand for upgrades in public hospitals and grassroots medical institutions [4] - The policy encourages the replacement of outdated blood dialysis equipment, allowing the company to benefit from increased procurement in hospitals and private dialysis centers [5] Financial Performance - In the first three quarters of 2025, the subsidiary Suzhou Junkang reported revenue of CNY 74.15 million and a net profit of CNY 5.23 million, with production capacity gradually being released [6] - The company’s blood dialysis products have seen a 121.29% increase in overseas revenue in the first half of 2025, indicating a positive trend in international market expansion [8] Market Growth and Projections - The number of patients undergoing hemodialysis in 2024 is projected to reach 1.027 million, maintaining a compound annual growth rate of approximately 12% over the past decade [9][10] - The peritoneal dialysis market is also expected to grow, with patient numbers projected to increase by over 10% annually, driven by supportive policies and greater awareness [10] Conclusion - The company is well-positioned to capitalize on market opportunities through innovative product offerings and favorable government policies, aiming for enhanced market penetration and improved patient care outcomes [1][4][5]

Group 1: International Market Expansion - As of the end of Q3 2025, the company's cumulative installed capacity for international business reached 11,214.62 MW, with over 3 GW installed in Asia (excluding China) and more than 2 GW in South America and Oceania, while North America and Africa each exceeded 1 GW [2] - The company had a total of 7,161.72 MW in external orders for overseas projects as of September 30, 2025 [2] Group 2: Domestic Wind Power Operations - The total equity installed capacity of the company's domestic and international self-operated wind farms reached 8,688 MW, with 28% in East China, 27% in Northwest China, 19% in North China, 12% in Northeast China, 9% in Southern China, and 5% internationally [2] - The company has 4,062 MW of domestic wind farm capacity under construction [2] - From January to September 2025, the company added 745 MW of new equity grid-connected capacity and sold wind farm capacity of 100 MW, with an average utilization hour of 1,730 hours for self-operated wind farms [2] Group 3: Mixed Tower Business Progress - In 2024, the company launched a new 204-meter digital steel-concrete tower platform, setting a new height record in the wind power industry [4] - The company secured its first international project using its mixed tower solution, marking a significant step in its mixed tower strategy [4] - In the first half of 2025, new domestic mixed tower orders increased by 50% year-on-year, and delivery volume rose by 59%, with 3 GW of international project orders obtained [4] Group 4: Research and Development Innovation - The company has established a global network of six R&D bases, including a headquarters in Beijing and an innovation center in Xinjiang, to drive cutting-edge technology development [5] - The company has implemented multiple innovation incentive systems and established mechanisms for discovering, cultivating, and incentivizing technological talent [5] - As of mid-2025, the company held 6,245 domestic patent applications, with 3,803 being invention patents (61% of total), and 4,611 domestic authorized patents, including 2,356 invention patents (51%), ranking first in the industry [5] - The company also has 1,423 overseas patent applications and 894 overseas authorized patents [5]

Group 1: Company Overview - Shandong Kuntai New Materials Technology Co., Ltd. specializes in automotive soft interior materials, focusing on R&D, production, and sales [2] - The company was listed on the Shenzhen Stock Exchange on February 16, 2023, under the stock code 001260 [2] - Core business includes a full industry chain for automotive soft interior materials, with main products like tufted carpets and needle-punched carpets [2][3] Group 2: Market and Partnerships - Kuntai has established stable partnerships with brands such as BMW, Audi, Mercedes-Benz, Volvo, Hongqi, NIO, Li Auto, and Xpeng [3] - The company is actively expanding its overseas market presence with subsidiaries in the USA, Singapore, Mexico, and Morocco [3] Group 3: Production Facilities - The Mexican production facility is in the early stage of small-batch trial production, with equipment installed and debugged [3] - The Moroccan production base is progressing with administrative approvals and has received strategic orders from important clients [3]